BioCentury | Nov 2, 2015
Company News

Biscayne Pharmaceuticals, Insero Health deal

...financial terms, and Insero did not respond to inquiries. Biscayne Pharmaceuticals Inc. , Miami, Fla. Insero Health Inc....
BioCentury | Sep 12, 2013
Distillery Therapeutics

Indication: Neurology

...Mnemosyne Pharmaceuticals Inc. has GRIN2A-selective NMDAR modulators in preclinical development for schizophrenia, depression and autism. Insero Health Inc....
BioCentury | Jun 17, 2013
Clinical News

INS001: Phase Ib data

...electrical stability. Data were presented at the Antiepileptic Drug and Device Trials meeting in Aventura. Insero Health Inc....
BioCentury | Feb 21, 2013
Distillery Therapeutics

Indication: Neurology

...of the rats. Next steps include characterizing huperzine A in additional rodent models of SCI. Insero Health Inc....
...page 4). SciBX 6(7); doi:10.1038/scibx.2013.170 Published online Feb. 21, 2013 Findings patented; exclusively licensed to Insero Health...
BioCentury | Feb 21, 2013
Targets & Mechanisms

Huperzine A in SCI

...small molecule huperzine A can reduce neuropathic pain in rats with spinal cord injury. 1 Insero Health Inc....
...professor of neurology at Harvard Medical School and chairman of the scientific advisory board for Insero Health...
...Published online Feb. 21, 2013 Companies and Institutions Mentioned Harvard Medical School , Boston, Mass. Insero Health Inc....
BioCentury | Feb 6, 2012
Financial News

Insero Health completes venture financing

Insero Health Inc. , Miami, Fla. Business: Neurology Date completed: 2/2/12 Type: Venture financing Raised: $1.1 million Investor: Reich Group WIR Staff Neurology...
BioCentury | Feb 6, 2012
Company News

Insero Health, Harvard, Yale University deal

...manufacturing process for huperzine, a compound derived from a botanical extract. Details were not disclosed. Insero Health Inc....
BioCentury | Feb 6, 2012
Company News

Insero Health board of directors update

Insero Health Inc. , Miami, Fla. Business: Neurology Appointed: Samuel Reich, managing partner of the Reich Group, as chairman WIR Staff Neurology...
BioCentury | Feb 3, 2012
Financial News

Insero Health debuts with $1.1 million

Insero Health Inc. (Miami, Fla.) raised $1.1 million in a seed round from the Reich Group. Insero is developing huperzine for epilepsy and related diseases. The NMDA receptor antagonist and acetylcholinesterase (AChE) inhibitor is slated...
Items per page:
1 - 9 of 9
BioCentury | Nov 2, 2015
Company News

Biscayne Pharmaceuticals, Insero Health deal

...financial terms, and Insero did not respond to inquiries. Biscayne Pharmaceuticals Inc. , Miami, Fla. Insero Health Inc....
BioCentury | Sep 12, 2013
Distillery Therapeutics

Indication: Neurology

...Mnemosyne Pharmaceuticals Inc. has GRIN2A-selective NMDAR modulators in preclinical development for schizophrenia, depression and autism. Insero Health Inc....
BioCentury | Jun 17, 2013
Clinical News

INS001: Phase Ib data

...electrical stability. Data were presented at the Antiepileptic Drug and Device Trials meeting in Aventura. Insero Health Inc....
BioCentury | Feb 21, 2013
Distillery Therapeutics

Indication: Neurology

...of the rats. Next steps include characterizing huperzine A in additional rodent models of SCI. Insero Health Inc....
...page 4). SciBX 6(7); doi:10.1038/scibx.2013.170 Published online Feb. 21, 2013 Findings patented; exclusively licensed to Insero Health...
BioCentury | Feb 21, 2013
Targets & Mechanisms

Huperzine A in SCI

...small molecule huperzine A can reduce neuropathic pain in rats with spinal cord injury. 1 Insero Health Inc....
...professor of neurology at Harvard Medical School and chairman of the scientific advisory board for Insero Health...
...Published online Feb. 21, 2013 Companies and Institutions Mentioned Harvard Medical School , Boston, Mass. Insero Health Inc....
BioCentury | Feb 6, 2012
Financial News

Insero Health completes venture financing

Insero Health Inc. , Miami, Fla. Business: Neurology Date completed: 2/2/12 Type: Venture financing Raised: $1.1 million Investor: Reich Group WIR Staff Neurology...
BioCentury | Feb 6, 2012
Company News

Insero Health, Harvard, Yale University deal

...manufacturing process for huperzine, a compound derived from a botanical extract. Details were not disclosed. Insero Health Inc....
BioCentury | Feb 6, 2012
Company News

Insero Health board of directors update

Insero Health Inc. , Miami, Fla. Business: Neurology Appointed: Samuel Reich, managing partner of the Reich Group, as chairman WIR Staff Neurology...
BioCentury | Feb 3, 2012
Financial News

Insero Health debuts with $1.1 million

Insero Health Inc. (Miami, Fla.) raised $1.1 million in a seed round from the Reich Group. Insero is developing huperzine for epilepsy and related diseases. The NMDA receptor antagonist and acetylcholinesterase (AChE) inhibitor is slated...
Items per page:
1 - 9 of 9